NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Single Technology Appraisal (STA)

Bevacizumab for the treatment of recurrent advanced ovarian cancer [ID490]

Please sign and return to:

Marcia Miller, Technology Appraisal Administrator Email: TACommA@nice.org.uk

Fax: +44 (0)20 7061 9721

Post: NICE, MidCity Place, 71 High Holborn, London, WC1V 6NA

I confirm that:

 I agree with the content of the statement submitted by NCRI/RCP/RCR/ACP/JCCO and consequently I will not be submitting a personal statement.

Name: Professor Charlie Gourley

Signed:

Date: 04/01/2013